- 期刊
- OpenAccess
Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma
並列摘要
Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment of advanced HCC. Several promising target-based drugs have been tested in a number of clinical trials. One breakthrough of these efforts is the approved clinical use of sorafenib in patients with advanced HCC. Targeted therapies are becoming an attractive option for the treatment of advanced HCC. In this review, we summarize the most recent progress in clinical targeted treatments of advanced HCC.
延伸閱讀
- 陳怡岑、喻絹惠（2016）。Target Therapy and Healthcare Complications for Patients with Advanced-Stage Hepatocellular Carcinoma。榮總護理，33(2)，141-152。https://doi.org/10.6142/VGHN.33.2.141
- Huang, G. T., Liang, J. D., & Sheu, J. C. (2004). Current Role of Local Ablative Treatments for Hepatocellular Carcinoma. Journal of the Formosan Medical Association, 103(6), 403-410. https://doi.org/10.29828/JFMA.200406.0002
- Hsu, J. C., Cheng, C. H., & Cheng, A. L. (2004). Recent Advances in Non-Surgical Treatment for Advanced Hepatocellular Carcinoma. Journal of the Formosan Medical Association, 103(7), 483-495. https://doi.org/10.29828/JFMA.200407.0002
- 許駿（2004）。Study of Systemic Therapy for Hepatocellular Carcinoma〔博士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2004.01876
- 劉鐘軒、蔡正中、陳海雄（2013）。The Diagnosis and Treatment Strategy of Hepatocellular Carcinoma。內科學誌，24(2)，85-94。https://doi.org/10.6314/JIMT.2013.24(2).02